In what is expected to produce hefty saving for rheumatoid arthritis patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).
In what is expected to produce hefty savings for rheumatoid arthritis (RA) patients and the healthcare system, FDA approved the second biosimilar to Remicade (Johnson & Johnson).
Samsung Bioepis Co.’s infliximab-abda (Renflexis) was just approved, after FDA approved the biosimilar infliximab-dyyb (Inflectra, Pfizer and Celltrion) last year. The new drug will be marketed and distributed in the United States by Merck.
Related: Another win for biosimilar arthritis drugs
Renflexis, the first drug for Samsung Bioepsis in the United States, is indicated for reducing signs and symptoms in patients with RA, adult and pediatric Crohn’s disease, adult ulcerative colitis, ankylosing spondylitis and psoriatic arthritis, and for the treatment of adult plaque psoriasis.
“Since our company was established five years ago, we have strived day in and day out to realize the promise of biosimilars for patients across the US by offering them treatment options at a lower cost. We hope this regulatory milestone will bring us a step closer to achieving this goal,” said Christopher Hansung Ko, president and CEO of Samsung Bioepis, in a statement from the company.
Related: Biosimilar approvals deemed “too slow”
The new biosimilar is also expected to impact Johnson & Johnson’s U.S. Remicade sales, which reached $4.84 billion in 2016.
Renflexis has also been approved in 28 European Union (EU) member states, Norway, Liechtenstein, Iceland, Australia and Korea.
Read more: First once-daily RA drug approved
FDA Approves Xolremdi for Ultra Rare Immune Disorder
April 29th 2024Xolremdi is the first therapy for WHIM syndrome, which can cause recurrent lung infections and papillomavirus-related warts. It’s available in two doses: 400 mg for an annual cost of $496,400 and 300 mg for an annual cost of $372,300.
FDA Approves Pfizer’s Gene Therapy Beqvez for Hemophilia
April 26th 2024Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.